SEC charges Cassava Sciences, founder, and ex-VP $40M for misleading statements on Alzheimer's treatment trial, no admission of guilt.

The SEC has charged Cassava Sciences and two former executives for making misleading statements regarding a clinical trial for an Alzheimer's treatment. The company, along with founder Remi Barbier and ex-vice president Dr. Lindsay Burns, will pay over $40 million to settle the charges without admitting wrongdoing. The company has cooperated with the investigation and implemented corrective measures, allowing it to focus on ongoing clinical trials.

September 26, 2024
17 Articles